PharmaTher Holdings Provides Update for KETARX™ (Racemic Ketamine) Development Programs and Expected Milestones for 2023
January 11, 2023 08:15 ET
|
PharmaTher Holdings Ltd.
Company aims to commercialize wholly-owned KETARX™ (racemic ketamine) for mental health, neurological and pain disorders Company aims to seek FDA approvals for KETARX™ via the ANDA and 505(b)(2)...
PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation
December 15, 2022 07:59 ET
|
PharmaTher Holdings Ltd.
TORONTO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, today announced that...
PharmaTher Announces Poster Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at Neuroscience 2022 by the Society for Neuroscience
November 14, 2022 07:59 ET
|
PharmaTher Holdings Ltd.
Seeking guidance from FDA to proceed towards a Phase 3 clinical study of KETARX™ (ketamine) for Parkinson’s disease under the 505(b)(2) regulatory pathway Ketamine was safe, well-tolerated with...
PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome
November 01, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on developing and...
PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson’s Disease
October 05, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
Grant of US patent strengthens the PharmaTher’s intellectual property portfolio covering novel uses and delivery forms of ketamine Announced positive efficacy and safety data from Phase 1/2 clinical...
PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022
September 29, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
Nearly $12 million in cash and investment Fully funded for the Company’s development programs, including ketamine injection and infusion products, ketamine microneedle patch and ketamine...
PharmaTher Announces Late-Breaking Abstract Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at the MDS International Congress of Parkinson's Disease and Movement Disorders®
September 16, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
Ketamine was safe, well-tolerated with 100% of patients treated with ketamine demonstrating reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale (UDysRS) UDysRS showed a 51%...
PharmaTher Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with KETARX™ Ketamine Patch
September 07, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
KETARX™ Ketamine Patch demonstrated extended delivery of ketamine over 40 hours KETARX™ Ketamine Patch offers flexible dosing through increased size, drug load or concentration of ketamine to better...
PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson’s Disease and Motor Disorders
July 13, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, July 13, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, announced today that...
PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch
June 29, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
Successfully delivered ketamine and KETABET™ (ketamine and betaine) via microneedle patch, unlocking the potential for desired dosage forms and pharmacokinetic profiles Pursuing Phase 2 clinical...